ClinicalTrials.gg
CompletedNCT01464931Updated Feb 19, 2016Results posted

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

A Phase 1 interventional study of Denosumab in Renal Impairment, sponsored by Amgen. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-19.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
216th of 468
32 · median 32
Started
2011
with 29 others
Phase 1
232 of 553
14 open now
Registered
206th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 216th largest by enrollment of the 468 interventional ones that give a count, is one of 30 that started in 2011, is one of 232 in phase 1, and was the 206th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects at least 18 years old with severe CKD (defined as \< 30 mL/min at both screening assessments) and CKD requiring hemodialysis
  • Additional inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Subjects must have calcium, phosphate, and magnesium levels appropriate for their condition and must not have other uncontrolled co-morbidities.
  • Additional exclusion criteria apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Denosumab

    Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.

    Drug: Denosumab

Interventions

  • Adminstered by subcutaneous injection

    Also known as: XGEVA, AMG 162

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Hypocalcemia

    Clinically significant hypocalcemia is defined as albumin-adjusted calcium \< 7.0 mg/dL or symptomatic hypocalcemia. Symptomatic hypocalcemiais is defined as both a clinical adverse event of hypocalcemia and a concomitant symptom of hypocalcemia (e.g., hypoesthesia, paresthesia, muscle cramps, seizure, prolonged QT interval) that occurred along with the hypocalcemia event or decreased serum calcium levels.

    Time frame: 113 days

Secondary outcomes

  1. Number of Participants With Hypocalcemia Determined by CTCAE v.4.0 Criteria

    The severity of hypocalcemia (a low concentration of calcium, corrected for albumin, in the blood) was graded according to the common terminology criteria for adverse events (CTCAE) v.4.0 criteria: Grade 1: albumin-adjusted serum calcium \< lower limit of normal (LLN; 9.2 mg/dL) to 8.0 mg/dL; Grade 2: albumin-adjusted serum calcium \< 8.0 to 7.0 mg/dL; Grade 3: albumin-adjusted serum calcium \< 7.0 to 6.0 mg/dL; Grade 4: albumin-adjusted serum calcium \< 6.0 mg/dL.

    Time frame: 113 days

  2. Number of Participants With Hypophosphatemia Determined by CTCAE v.4.0 Criteria

    The severity of hypophosphatemia (a low concentration of phosphates in the blood) was graded according to the common terminology criteria for adverse events (CTCAE) v.4.0 criteria: Grade 1: \< LLN (3 mg/dL) - 2.5 mg/dL; Grade 2: \< 2.5 - 2.0 mg/dL; Grade 3: \< 2.0 - 1.0 mg/dL; Grade 4: \< 1.0 mg/dL.

    Time frame: 113 days

  3. Number of Participants With Hypomagnesemia Determined by CTCAE v.4.0 Criteria

    The severity of hypomagnesemia (a low concentration of magnesium in the blood) was graded according to the common terminology criteria for adverse events (CTCAE) v.4.0 criteria: Grade 1: \< LLN (1.5 mg/dL) - 1.2 mg/dL; Grade 2: \< 1.2 - 0.9 mg/dL; Grade 3: \< 0.9 - 0.7 mg/dL; Grade 4: \< 0.7 mg/dL.

    Time frame: 113 days

  4. Percent Change From Baseline in Albumin-adjusted Serum Calcium Over Time

    Time frame: Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113

  5. Percent Change From Baseline in Serum Phosphorus Over Time

    Time frame: Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113

  6. Percent Change From Baseline in Serum Magnesium Over Time

    Time frame: Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113

  7. Number of Participants With Adverse Events

    The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The investigator assessed whether AEs were possibly related to study drug by answering the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?" Abnormal laboratory findings without clinical significance (based on the investigator's judgment) were not recorded as AEs, however, laboratory value changes that required treatment or adjustment in current therapy were considered AEs. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal, • life-threatening (places the participant at immediate risk of death), • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other medically important serious event.

    Time frame: 113 days

  8. Maximum Observed Serum Denosumab Concentration (Cmax)

    Serum concentrations of denosumab were measured by an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 20 ng/mL.

    Time frame: Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113

  9. Time to Maximum Observed Serum Denosumab Concentration (Tmax)

    Serum concentrations of denosumab were measured by an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 20 ng/mL.

    Time frame: Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113

  10. Area Under the Serum Concentration-time Curve From Time 0 to 4 Weeks (AUC0-4wks) After Dose 1

    Estimated using the linear trapezoidal method.

    Time frame: Days 1, 8, 15, and 29 (predose)

  11. Area Under the Serum Concentration-time Curve From Time 0 to 12 Weeks (AUC0-12wks) After Dose 2

    Estimated using the linear trapezoidal method.

    Time frame: Days 29 (predose), 36, 43, 57, 71, and 85

  12. Percent Change From Baseline in Serum C-Telopeptide Over Time

    Time frame: Baseline and Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113

  13. Number of Participants Who Developed Anti-denosumab Antibodies

    Time frame: From Day 1 (predose) to Day 113

07

Results

Posted Feb 19, 2016

Participant flow

Participant flow — Overall Study
MilestoneSevere CKDESRD
Started1616
Completed1516
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Participants With Clinically Significant Hypocalcemia

Clinically significant hypocalcemia is defined as albumin-adjusted calcium \< 7.0 mg/dL or symptomatic hypocalcemia. Symptomatic hypocalcemiais is defined as both a clinical adverse event of hypocalcemia and a concomitant symptom of hypocalcemia (e.g., hypoesthesia, paresthesia, muscle cramps, seizure, prolonged QT interval) that occurred along with the hypocalcemia event or decreased serum calcium levels.

Time frame:
113 days
Reported as:
Number · participants
Number of Participants With Clinically Significant Hypocalcemia
participantsSevere CKDESRD
Number of Participants With Clinically Significant Hypocalcemia12
SecondaryNumber of Participants With Hypocalcemia Determined by CTCAE v.4.0 Criteria

The severity of hypocalcemia (a low concentration of calcium, corrected for albumin, in the blood) was graded according to the common terminology criteria for adverse events (CTCAE) v.4.0 criteria: Grade 1: albumin-adjusted serum calcium \< lower limit of normal (LLN; 9.2 mg/dL) to 8.0 mg/dL; Grade 2: albumin-adjusted serum calcium \< 8.0 to 7.0 mg/dL; Grade 3: albumin-adjusted serum calcium \< 7.0 to 6.0 mg/dL; Grade 4: albumin-adjusted serum calcium \< 6.0 mg/dL.

Time frame:
113 days
Reported as:
Number · participants
Number of Participants With Hypocalcemia Determined by CTCAE v.4.0 Criteria
participantsSevere CKDESRD
Grade 1126
Grade 239
Grade 301
Grade 400
SecondaryNumber of Participants With Hypophosphatemia Determined by CTCAE v.4.0 Criteria

The severity of hypophosphatemia (a low concentration of phosphates in the blood) was graded according to the common terminology criteria for adverse events (CTCAE) v.4.0 criteria: Grade 1: \< LLN (3 mg/dL) - 2.5 mg/dL; Grade 2: \< 2.5 - 2.0 mg/dL; Grade 3: \< 2.0 - 1.0 mg/dL; Grade 4: \< 1.0 mg/dL.

Time frame:
113 days
Reported as:
Number · participants
Number of Participants With Hypophosphatemia Determined by CTCAE v.4.0 Criteria
participantsSevere CKDESRD
Grade 100
Grade 221
Grade 305
Grade 400
SecondaryNumber of Participants With Hypomagnesemia Determined by CTCAE v.4.0 Criteria

The severity of hypomagnesemia (a low concentration of magnesium in the blood) was graded according to the common terminology criteria for adverse events (CTCAE) v.4.0 criteria: Grade 1: \< LLN (1.5 mg/dL) - 1.2 mg/dL; Grade 2: \< 1.2 - 0.9 mg/dL; Grade 3: \< 0.9 - 0.7 mg/dL; Grade 4: \< 0.7 mg/dL.

Time frame:
113 days
Reported as:
Number · participants
Number of Participants With Hypomagnesemia Determined by CTCAE v.4.0 Criteria
participantsSevere CKDESRD
Grade 120
Grade 200
Grade 300
Grade 400
SecondaryPercent Change From Baseline in Albumin-adjusted Serum Calcium Over Time
Time frame:
Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113
Reported as:
Median · percent change
Percent Change From Baseline in Albumin-adjusted Serum Calcium Over Time
percent changeSevere CKDESRD
Day 2 (N=16, 16)-0.55 ± 3.561.21 ± 4.66
Day 3 (N=16, 16)-3.20 ± 5.99-1.86 ± 5.82
Day 6 (N=16, 16)-4.27 ± 7.42-7.34 ± 8.75
Day 8 (N=15, 16)-3.11 ± 5.77-9.75 ± 9.88
Day 11 (N=16, 16)-5.10 ± 5.07-5.51 ± 6.78
Day 15 (N=16, 16)-0.49 ± 5.19-6.36 ± 9.79
Day 22 (N=14, 15)-3.74 ± 7.28-4.26 ± 8.57
Day 29 (N=15, 16)-1.17 ± 3.77-5.87 ± 12.34
Day 30 (N=15, 16)-1.08 ± 3.64-2.17 ± 9.73
Day 31 (N=15, 16)-1.03 ± 4.76-2.29 ± 10.16
Day 34 (N=15, 16)0.00 ± 6.07-2.85 ± 13.42
Day 36 (N=14, 16)-1.08 ± 6.94-1.11 ± 7.39
Day 39 (N=16, 15)-0.60 ± 5.15-1.93 ± 7.79
Day 43 (N=15, 15)-1.04 ± 7.91-0.82 ± 6.78
Day 57 (N=15, 16)-2.08 ± 5.52-1.64 ± 11.11
Day 71 (N=15, 16)2.06 ± 5.56-4.98 ± 9.38
Day 85 (N=14, 15)1.06 ± 6.37-6.87 ± 10.81
Day 113 (N=15, 16)0.00 ± 9.48-4.88 ± 7.94
SecondaryPercent Change From Baseline in Serum Phosphorus Over Time
Time frame:
Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113
Reported as:
Median · percent change
Percent Change From Baseline in Serum Phosphorus Over Time
percent changeSevere CKDESRD
Day 2 (N=16, 15)-5.97 ± 10.42-20.00 ± 15.51
Day 3 (N=16, 15)-10.37 ± 15.25-25.93 ± 24.26
Day 6 (N=16, 15)-19.09 ± 15.81-24.56 ± 26.43
Day 8 (N=15, 16)-13.46 ± 14.96-31.16 ± 35.81
Day 11 (N=16, 14)-19.38 ± 10.93-33.29 ± 29.13
Day 15 (N=16, 16)-10.00 ± 9.15-27.64 ± 26.62
Day 22 (N=15, 16)-15.38 ± 17.27-25.89 ± 34.20
Day 29 (N=15, 16)-5.13 ± 13.22-21.64 ± 22.06
Day 30 (N=15, 15)-5.71 ± 13.63-31.25 ± 20.94
Day 31 (N=15, 15)-7.14 ± 13.20-19.30 ± 20.69
Day 34 (N=15, 15)-5.41 ± 14.23-15.00 ± 28.53
Day 36 (N=14, 16)-4.84 ± 13.80-19.38 ± 18.77
Day 39 (N=16, 14)-8.30 ± 11.72-18.89 ± 21.00
Day 43 (N=15, 15)-6.82 ± 16.53-6.25 ± 30.76
Day 57 (N=15, 16)-11.43 ± 11.65-7.18 ± 30.00
Day 71 (N=15, 16)-3.45 ± 16.32-0.05 ± 45.15
Day 85 (N=15, 16)-7.69 ± 14.51-6.04 ± 30.74
Day 113 (N=15, 16)-7.14 ± 10.07-8.99 ± 33.92
SecondaryPercent Change From Baseline in Serum Magnesium Over Time
Time frame:
Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113
Reported as:
Median · percent change
Percent Change From Baseline in Serum Magnesium Over Time
percent changeSevere CKDESRD
Day 2 (N=16, 15)0.00 ± 7.54-3.85 ± 7.47
Day 3 (N=16, 15)0.00 ± 10.940.00 ± 6.65
Day 6 (N=16, 15)2.50 ± 8.584.00 ± 14.39
Day 8 (N=15, 16)4.76 ± 7.470.00 ± 10.46
Day 11 (N=16, 14)2.38 ± 10.290.00 ± 6.12
Day 15 (N=16, 16)0.00 ± 10.780.00 ± 7.88
Day 22 (N=15, 16)10.53 ± 9.140.00 ± 9.24
Day 29 (N=15, 16)0.00 ± 9.872.27 ± 12.57
Day 30 (N=15, 15)0.00 ± 16.15-4.55 ± 8.87
Day 31 (N=15, 15)0.00 ± 12.460.00 ± 7.94
Day 34 (N=15, 15)0.00 ± 7.790.00 ± 7.85
Day 36 (N=14, 16)0.00 ± 9.79-4.45 ± 7.47
Day 39 (N=16, 14)0.00 ± 12.06-4.35 ± 8.68
Day 43 (N=15, 15)0.00 ± 8.313.45 ± 9.00
Day 57 (N=15, 16)5.00 ± 15.870.00 ± 8.50
Day 71 (N=15, 16)0.00 ± 9.150.00 ± 11.74
Day 85 (N=15, 16)0.00 ± 9.214.12 ± 12.40
Day 113 (N=15, 16)0.00 ± 11.871.92 ± 9.46
SecondaryNumber of Participants With Adverse Events

The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The investigator assessed whether AEs were possibly related to study drug by answering the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?" Abnormal laboratory findings without clinical significance (based on the investigator's judgment) were not recorded as AEs, however, laboratory value changes that required treatment or adjustment in current therapy were considered AEs. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal, • life-threatening (places the participant at immediate risk of death), • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other medically important serious event.

Time frame:
113 days
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsSevere CKDESRD
Any adverse event (AE)1015
Adverse events Grade >=337
Serious adverse events12
Leading to discontinuation of study drug00
Leading to discontinuation from study00
Fatal adverse events00
Hypocalcemia adverse events310
Hypomagnesemia adverse events00
Hypophosphatemia adverse events01
Treatment-related adverse events (TRAE)210
Treatment-related adverse events Grade >=302
Treatment-related serious adverse events00
TRAE leading to discontinuation of study drug00
TRAE leading to study discontinuation00
SecondaryMaximum Observed Serum Denosumab Concentration (Cmax)

Serum concentrations of denosumab were measured by an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 20 ng/mL.

Time frame:
Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113
Reported as:
Mean · μg/mL
Maximum Observed Serum Denosumab Concentration (Cmax)
μg/mLSevere CKD - Dose 1ESRD - Dose 1Severe CKD - Dose 2ESRD - Dose 2
Maximum Observed Serum Denosumab Concentration (Cmax)10.5 ± 3.68.17 ± 4.2216.1 ± 5.214.5 ± 7.4
SecondaryTime to Maximum Observed Serum Denosumab Concentration (Tmax)

Serum concentrations of denosumab were measured by an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 20 ng/mL.

Time frame:
Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113
Reported as:
Median · days
Time to Maximum Observed Serum Denosumab Concentration (Tmax)
daysSevere CKD - Dose 1ESRD - Dose 1Severe CKD - Dose 2ESRD - Dose 2
Time to Maximum Observed Serum Denosumab Concentration (Tmax)14 ± 3.614 ± 4.2214 ± 5.27.0 ± 7.4
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to 4 Weeks (AUC0-4wks) After Dose 1

Estimated using the linear trapezoidal method.

Time frame:
Days 1, 8, 15, and 29 (predose)
Reported as:
Mean · μg*day/mL
Area Under the Serum Concentration-time Curve From Time 0 to 4 Weeks (AUC0-4wks) After Dose 1
μg*day/mLSevere CKD - Dose 1ESRD - Dose 1
Area Under the Serum Concentration-time Curve From Time 0 to 4 Weeks (AUC0-4wks) After Dose 1233 ± 75177 ± 91
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to 12 Weeks (AUC0-12wks) After Dose 2

Estimated using the linear trapezoidal method.

Time frame:
Days 29 (predose), 36, 43, 57, 71, and 85
Reported as:
Mean · μg*day/mL
Area Under the Serum Concentration-time Curve From Time 0 to 12 Weeks (AUC0-12wks) After Dose 2
μg*day/mLSevere CKD - Dose 2ESRD - Dose 2
Area Under the Serum Concentration-time Curve From Time 0 to 12 Weeks (AUC0-12wks) After Dose 2853 ± 260607 ± 262
SecondaryPercent Change From Baseline in Serum C-Telopeptide Over Time
Time frame:
Baseline and Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113
Reported as:
Median · percent change
Percent Change From Baseline in Serum C-Telopeptide Over Time
percent changeSevere CKDESRD
Day 8 (N=15, 16)-63.0 ± 24.3-79.1 ± 13.6
Day 15 (N=16, 16)-60.7 ± 23.6-79.3 ± 11.9
Day 29 (N=15, 16)-58.4 ± 24.7-81.5 ± 12.3
Day 36 (N=15, 16)-63.0 ± 24.2-79.4 ± 13.1
Day 43 (N=15, 15)-58.4 ± 24.5-77.7 ± 13.4
Day 57 (N=15, 16)-58.4 ± 24.0-81.7 ± 11.7
Day 71 (N=15, 16)-58.4 ± 24.0-76.4 ± 13.8
Day 85 (N=15, 16)-57.4 ± 24.0-75.9 ± 12.0
Day 113 (N=15, 16)-50.2 (-75.0 to -39.4)-75.6 (-88.5 to -63.3)
SecondaryNumber of Participants Who Developed Anti-denosumab Antibodies
Time frame:
From Day 1 (predose) to Day 113
Reported as:
Number · participants
Number of Participants Who Developed Anti-denosumab Antibodies
participantsSevere CKDESRD
Number of Participants Who Developed Anti-denosumab Antibodies00

Adverse events

Collected over 113 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 120 mg - Severe—1/16 (6.3%)10/16 (62.5%)
Denosumab 120 mg - ESRD—2/16 (12.5%)15/16 (93.8%)
Denosumab 120 mg - All Subjects—3/32 (9.4%)25/32 (78.1%)
Most frequent serious events
Most frequent serious events
EventDenosumab 120 mg - SevereDenosumab 120 mg - ESRDDenosumab 120 mg - All Subjects
IleitisGastrointestinal disorders0/161/161/32
AstheniaGeneral disorders1/160/161/32
Non-cardiac chest painGeneral disorders0/161/161/32
Most frequent other events
Showing 10 of 44
Most frequent other events
EventDenosumab 120 mg - SevereDenosumab 120 mg - ESRDDenosumab 120 mg - All Subjects
HypocalcaemiaMetabolism and nutrition disorders2/1610/1612/32
HypercalcaemiaMetabolism and nutrition disorders2/163/165/32
DiarrhoeaGastrointestinal disorders2/161/163/32
Upper respiratory tract infectionInfections and infestations0/162/162/32
AnaemiaBlood and lymphatic system disorders1/160/161/32
Angina pectorisCardiac disorders0/161/161/32
PericarditisCardiac disorders0/161/161/32
Sinus tachycardiaCardiac disorders0/161/161/32
Ventricular extrasystolesCardiac disorders0/161/161/32
Hearing impairedEar and labyrinth disorders0/161/161/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Severe CKDESRDTotal
Mean79.2 ± 9.565.9 ± 12.472.5 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Severe CKDESRDTotal
Female9716
Male7916
08

Study locations

7 sites
  • Research Site
    Tempe, Arizona 85284, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Pembroke Pines, Florida 33028, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Detroit, Michigan 48236, United States
  • Research Site
    Orangeburg, South Carolina 29118, United States
  • Research Site
    San Antonio, Texas 78215, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2011
First posted
Nov 4, 2011
Start
Nov 2011
Primary completionActual
Jan 2013
CompletionActual
Mar 2013
Results first posted
Feb 19, 2016
Last update
Feb 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01464931
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 4, 2011
Start date
Nov 2011
Primary completion
Jan 2013
Completion
Mar 2013
Results posted
Feb 19, 2016
Last update
Feb 19, 2016

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion